BioTech

Abbisko Therapeutics Collaborates With Eli Lilly For Research And Development; Stock Up

June 24, 2026 — 01:33 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Abbisko Therapeutics Co., Ltd. (2256.HK), an oncology-focused biopharmaceutical company, has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (LLY) to discover and develop medicines across multiple targets.

Abbisko will use its early-stage drug discovery platform and research and development capabilities to support drug discovery programs targeting disease areas selected by Lilly.

The companies previously entered into a global collaboration and exclusive licensing agreement in 2022 to develop small-molecule therapeutics.

Abbisko Therapeutics develops Pimicotinib (ABSK021), a small-molecule CSF-1R inhibitor, that is currently in the NDA stage for the treatment of tenosynovial giant cell tumours.

2256.HK has traded between a 52-week low of HK$8.34 and a high of HK$19.78.The stock is currently trading at HK$9.31 up 3.44%.

LLY has traded between $623.78 and $1,182.73 over the last year. LLY closed Tuesday's trade at $1107.08, up 0.45%. In the overnight market, LLY is up 0.15% at $1108.73.

For More Such Biotech Stock News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

BioTech
Stocks Mentioned
LLY

Latest Articles
Data is currently not available